CTXR
Citius Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.43
−7.00%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.45
From 52W high−76.49%
Volume526547.00
Market cap$11.74M
P/E (TTM)—
P/S (TTM)1.7x
Div yield—
Key dataOct 19, 2026
Open
$0.45
From 52W high
−76.49%
Volume
526547.00
Market cap
$11.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
30.8
MomentumView details →
1D Return
−7.00%
YTD Return
−43.06%
SummaryUpdated Jun 1, 2026
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey. The company went public in October 2014 and focuses on developing critical care products, particularly anti-infective treatments for cancer care, prescription therapeutics, and advanced stem cell therapies. As a clinical-stage biotechnology company, Citius has built a pipeline of five proprietary products targeting various medical conditions, from catheter-related infections to cancer treatments, though it has yet to generate substantial commercial revenues from these developments.
Similar companies
Latest newsMore news →
Citius Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, with $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR and $17 million in cash and cash equivalents as of June 30, 2026.66d agoCitius Oncology appointed Jonathan Peri as an independent director to its board.68d ago